Abstract
Hypocitraturia is a proven risk factor in recurrent urolithiasis. Citrate in urine chelates calcium ions and reduces the amount of calcium available for oxalate stone formation, thereby lessening the chances of stone formation. This study was conducted to determine the efficacy of different oral citrate drugs in altering urinary risk factors. The aim of the study was to identify a satisfactory citrate preparation for stone patients to increase the urinary citrate level.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media New York
About this chapter
Cite this chapter
Thomas, N.E., Roshni, S.V., Moorthy, H.K., Sindhu, S., Vathsala, R.K., Marickar, Y.M.F. (1994). Oral Citrate Therapy in Urolithiasis. In: Ryall, R., Bais, R., Marshall, V.R., Rofe, A.M., Smith, L.H., Walker, V.R. (eds) Urolithiasis 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2556-1_263
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2556-1_263
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6091-9
Online ISBN: 978-1-4615-2556-1
eBook Packages: Springer Book Archive